Margin fell 10.89 points as Gem Aromatics swung to a loss
Sequential revenue fell 10.47% while expenses rose 0.89%; management attributed the margin pressure to product mix, raw-material and operating costs.
Filed 13 Aug 2026, 17:54 IST · after market close · GEMAROMA (GEMAROMA)
Key takeaways
- Consolidated operating margin contracted 10.89 percentage points sequentially to 3.34%, as expenses rose 0.89% while revenue fell 10.47%.
- Consolidated net profit swung from Rs 1.01 cr to a loss of Rs 7.87 cr, with management citing Rs 9.1 cr of higher depreciation alongside cost pressure.
- Management said it is monetising the expanded Dahej platform after capitalising approximately Rs 265 cr of capex, with cooling-agent revenue contribution expected from Q3FY27.
Q1FY27 shifted from profit to loss
Gem Aromatics reported consolidated revenue down 10.47% sequentially, while operating profit fell 78.93% as the quarter moved from a Rs 1.01 cr net profit to a Rs 7.87 cr loss. The revenue decline came despite management describing Q1FY27 as seasonally softer and saying business activity had improved year on year. The company filed the results after market close.
Costs and depreciation compressed profitability
Expenses grew 0.89% even as revenue declined 10.47%, driving the 10.89-percentage-point contraction in operating margin. Management said product mix, higher raw-material costs and operating costs affected gross and EBITDA margins, while Rs 9.1 cr of higher depreciation also hurt profitability. Interest expense fell 3.03%, but depreciation rose 1.33%, limiting the benefit. Other income was only -1.87% of pre-tax profit, so it did not materially support earnings; the lower 7.83% tax rate reflected a tax credit in a loss-making quarter.
Dahej utilisation is management's stated route to recovery
Management said its focus is on utilising and monetising the expanded Dahej manufacturing platform and scaling newer product categories through Krystal Ingredients. The company said approximately Rs 265 cr of Dahej capex had been capitalised against planned capex of approximately Rs 270 cr, and that capacity was expanded in April 2026. Management also said margins should gradually improve as capacity utilisation rises and higher-value products contribute more.
New products provide the next milestones
Management said customer audits for GEM Cool 03, GEM Cool 05 and GEM Cool 23 were completed and initial orders were secured. It said cooling-agent revenue contribution is expected from Q3FY27, while phenol-derivative trial production is expected by the end of Q2FY27 and commercial production is targeted in Q3FY27. The company also said it approved a wholly owned Brazil subsidiary for distribution in Latin America.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹99 cr | ₹110 cr | -10.47% |
| Other income | ₹0 cr | ₹0 cr | -46.67% |
| Expenses | ₹96 cr | ₹95 cr | +0.89% |
| Operating profit | ₹3 cr | ₹16 cr | -78.93% |
| Operating margin (%) | 3.34% | 14.23% | — |
| Interest | ₹3 cr | ₹3 cr | -3.03% |
| Depreciation | ₹9 cr | ₹9 cr | +1.33% |
| Profit before tax | ₹-9 cr | ₹4 cr | — |
| Tax | ₹-1 cr | ₹3 cr | — |
| Net profit | ₹-8 cr | ₹1 cr | — |
| EPS (₹) | ₹-1.56 | ₹0.19 | — |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Q1FY27 revenue from operations grew year on year despite the quarter being seasonally softer.
- Customer audits for GEM Cool 03, GEM Cool 05 and GEM Cool 23 were completed and initial orders were secured.
Guidance & outlook
- Management is focusing on utilising and monetising the expanded Dahej manufacturing platform and scaling newer product categories through Krystal Ingredients.
- The company expects margins to gradually improve as capacity utilisation rises and higher-value products contribute more.
- The company aims to convert customer engagement and qualification opportunities into recurring commercial business as they scale.
Planned next quarter
- Cooling agent revenue contribution is expected from Q3FY27.
- Phenol derivative trial production is expected by the end of Q2FY27, with commercial production targeted in Q3FY27.
Expansion
- Approximately Rs 265 Cr of Dahej capex was capitalised, against total planned capex of approximately Rs 270 Cr.
- The company expanded capacity at the Dahej plant in April 2026.
- The company approved incorporation of a wholly owned Brazil subsidiary to distribute essential and specialty chemicals in Latin America.
New products
- The phenol derivatives portfolio includes Anethole, Anisole, MEHQ, BHA, Guaiacol and 4-MAP.
New initiatives
- The company is continuing R&D focused on process innovation, product customisation and higher-value specialty molecules.
- The Dahej facility can support CRO, CMO and CDMO manufacturing models.
Problems & risks
- Floods in Madagascar affected the Clove business, raising raw material prices and impacting sales.
- Gross and EBITDA margins were impacted by product mix and higher raw material costs.
- Profitability was affected by higher raw material and operating costs and Rs 9.1 Cr of additional depreciation.
What to watch
- Whether operating margin recovers from 3.34% as capacity utilisation and higher-value product contribution rise, as management said.
- Whether cooling agents begin contributing revenue from Q3FY27, as management said.
- Whether phenol-derivative trial production is completed by the end of Q2FY27 and commercial production progresses towards Q3FY27, as management said.